The formation of a Scientific Advisory Board by Tharimmune, especially with experts in relevant fields, is likely to positively impact its research and development efforts. This strategic move can enhance the company's capabilities in developing treatments for chronic liver disease and in the field of antibody drug conjugates, potentially leading to breakthroughs or advancements in their pipeline. Such developments are typically viewed positively by investors, as they can lead to increased valuation of the company's stock in anticipation of successful drug development and commercialization.